Related Experiment Videos
Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study
D Baettig1, G Bondolfi, S Montaldi
1Unité de Biochimie et Psychopharmacologie Clinique, Départment Universitaire de Psychiatrie Adulte, Prilly-Lausanne, Switzerland.
European Journal of Clinical Pharmacology
|January 1, 1993
Summary
Citalopram addition to amitriptyline treatment in depressed patients showed no impact on drug levels but improved symptoms. This suggests citalopram may not interact with tricyclic antidepressants like other SSRIs.
Area of Science:
- Pharmacology
- Clinical Psychiatry
- Neuroscience
Background:
- Tricyclic antidepressants (TCAs) like amitriptyline are standard treatments for depression.
- Selective serotonin reuptake inhibitors (SSRIs) are also widely used, but some can interact with TCAs.
- Potential drug interactions necessitate careful consideration of co-medication strategies.
Observation:
- A depressed patient received citalopram (40-60 mg/day) alongside amitriptyline (75 mg/day).
- Plasma levels of amitriptyline and its active metabolite, nortriptyline, were monitored.
- Clinical response and adverse effects were assessed during the co-medication period.
Findings:
- Citalopram co-administration did not alter plasma concentrations of amitriptyline or nortriptyline.
- The addition of citalopram resulted in significant clinical improvement in the patient.
- No adverse effects were reported during the combined treatment regimen.
Implications:
- Citalopram may possess a different pharmacokinetic interaction profile compared to other SSRIs (e.g., fluvoxamine, fluoxetine).
- This suggests citalopram could be a safer option for patients requiring combined TCA and SSRI therapy.
- Further research is warranted to confirm these findings in a larger patient cohort.